New hope for rare lung disease: JAK inhibitors vs standard care
NCT ID NCT07406932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether JAK inhibitors work better than calcineurin inhibitors as the first treatment for lung scarring in people with antisynthetase syndrome. About 80 adults with active lung disease will be followed for 12 months to see which drug improves breathing and survival more. The goal is to give doctors clearer guidance on the best starting therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTISYNTHETASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted immune drug calm rare muscle inflammation?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can an inhaled powder stop lung scarring? a safety trial begins
- Repairing lungs from within: stem cells harvested from Patients' own airways tested for scarring disease
- AI could uncover hidden lung disease in routine chest X-Rays
- Can oxygen during exercise supercharge lung rehab for ILD patients?